Journal of Veterinary Science

The Korean Society of Veterinary Science (대한수의학회)
권호 표지
DOI QR코드

DOI QR Code

Expression and evaluation of porcine circovirus type 2 capsid protein mediated by recombinant adeno-associated virus 8

  • Li, Shuang (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Wang, Bo (School of Chemistry and Life Science, Changchun University of Technology) ;
  • Jiang, Shun (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Lan, Xiaohui (The Second Hospital of Jilin University) ;
  • Qiao, Yongbo (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Nie, Jiaojiao (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Yin, Yuhe (School of Chemistry and Life Science, Changchun University of Technology) ;
  • Shi, Yuhua (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Kong, Wei (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University) ;
  • Shan, Yaming (National Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University)
  • Received : 2020.09.09
  • Accepted : 2020.11.29
  • Published : 2021.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Porcine circovirus type 2 (PCV2) is an important infectious pathogen implicated in porcine circovirus-associated diseases (PCVAD), which has caused significant economic losses in the pig industry worldwide. Objectives: A suitable viral vector-mediated gene transfer platform for the expression of the capsid protein (Cap) is an attractive strategy. Methods: In the present study, a recombinant adeno-associated virus 8 (rAAV8) vector was constructed to encode Cap (Cap-rAAV) in vitro and in vivo after gene transfer. Results: The obtained results showed that Cap could be expressed in HEK293T cells and BABL/c mice. The results of lymphocytes proliferative, as well as immunoglobulin G (IgG) 2a and interferon-γ showed strong cellular immune responses induced by Cap-rAAV. The enzyme-linked immunosorbent assay titers obtained and the IgG1 and interleukin-4 levels showed that humoral immune responses were also induced by Cap-rAAV. Altogether, these results demonstrated that the rAAV8 vaccine Cap-rAAV can induce strong cellular and humoral immune responses, indicating a potential rAAV8 vaccine against PCV2. Conclusions: The injection of rAAV8 encoding PCV2 Cap genes into muscle tissue can ensure long-term, continuous, and systemic expression.

Keywords

Acknowledgement

This work was supported by National Natural Science Foundation of China (grant number: 31770996).

References

  1. Zhang Z, Luo Y, Zhang Y, Guo K. Enhanced protective immune response to PCV2 adenovirus vaccine by fusion expression of Cap protein with InvC in pigs. J Vet Sci. 2019;20(4):e35. https://doi.org/10.4142/jvs.2019.20.e35
  2. Huang L, Sun Z, Xia D, Wei Y, Sun E, Liu C, et al. Neutralization mechanism of a monoclonal antibody targeting a porcine circovirus type 2 Cap protein conformational epitope. J Virol. 2020;94(9):e01836-19.
  3. Kim HK, Lyoo KS, Huynh TM, Moon HJ, Nguyen VG, Park BK. Duplex nested reverse transcriptase polymerase chain reaction for simultaneous detection of type 2 porcine reproductive and respiratory syndrome virus and porcine circovirus type 2 from tissue samples. J Vet Sci. 2017;18(2):253-256. https://doi.org/10.4142/jvs.2017.18.2.253
  4. Cao W, Cao H, Yi X, Zhuang Y. Development of a simple and high-yielding fed-batch process for the production of porcine circovirus type 2 virus-like particle subunit vaccine. AMB Express. 2019;9(1):164. https://doi.org/10.1186/s13568-019-0880-8
  5. Karuppannan AK, Opriessnig T. Porcine circovirus type 2 (PCV2) vaccines in the context of current molecular epidemiology. Viruses. 2017;9(5):99. https://doi.org/10.3390/v9050099
  6. Segales J. Best practice and future challenges for vaccination against porcine circovirus type 2. Expert Rev Vaccines. 2015;14(3):473-487. https://doi.org/10.1586/14760584.2015.983084
  7. Wang QH, Kuang N, Hu WY, Yin D, Wei YY, Hu TJ. The effect of Panax notoginseng saponins on oxidative stress induced by PCV2 infection in immune cells: in vitro and in vivo studies. J Vet Sci. 2020;21(4):e61. https://doi.org/10.4142/jvs.2020.21.e61
  8. Shin MK, Yoon SH, Kim MH, Lyoo YS, Suh SW, Yoo HS. Assessing PCV2 antibodies in field pigs vaccinated with different porcine circovirus 2 vaccines using two commercial ELISA systems. J Vet Sci. 2015;16(1):25-29. https://doi.org/10.4142/jvs.2015.16.1.25
  9. Huang L, Wei Y, Xia D, Liu D, Zhu H, Wu H, et al. A broad spectrum monoclonal antibody against porcine circovirus type 2 for antigen and antibody detection. Appl Microbiol Biotechnol. 2019;103(8):3453-3464. https://doi.org/10.1007/s00253-019-09715-0
  10. Eclercy J, Larcher T, Andraud M, Renson P, Bernard C, Bigault L, et al. PCV2 co-infection does not impact PRRSV MLV1 safety but enhances virulence of a PRRSV MLV1-like strain in infected SPF pigs. Vet Microbiol. 2020;244:108656. https://doi.org/10.1016/j.vetmic.2020.108656
  11. Wang X, Lv C, Ji X, Wang B, Qiu L, Yang Z. Ivermectin treatment inhibits the replication of porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets. Virus Res. 2019;263:80-86. https://doi.org/10.1016/j.virusres.2019.01.010
  12. Wei C, Lin Z, Dai A, Chen H, Ma Y, Li N, et al. Emergence of a novel recombinant porcine circovirus type 2 in China: PCV2c and PCV2d recombinant. Transbound Emerg Dis. 2019;66(6):2496-2506. https://doi.org/10.1111/tbed.13307
  13. Duan J, Yang D, Chen L, Yu Y, Zhou J, Lu H. Efficient production of porcine circovirus virus-like particles using the nonconventional yeast Kluyveromyces marxianus. Appl Microbiol Biotechnol. 2019;103(2):833-842. https://doi.org/10.1007/s00253-018-9487-2
  14. Wang T, Du Q, Wu X, Niu Y, Guan L, Wang Z, et al. Porcine MKRN1 modulates the replication and pathogenesis of porcine circovirus type 2 by inducing capsid protein ubiquitination and degradation. J Virol. 2018;92(11):e00100-18.
  15. Wang L, Zhao D, Sun B, Yu M, Wang Y, Ru Y, et al. Oral vaccination with the porcine circovirus type 2 (PCV-2) capsid protein expressed by Lactococcus lactis induces a specific immune response against PCV-2 in mice. J Appl Microbiol. 2020;128(1):74-87. https://doi.org/10.1111/jam.14473
  16. Li D, Du Q, Wu B, Li J, Chang L, Zhao X, et al. Immunogenicity of adenovirus vaccines expressing the PCV2 capsid protein in pigs. Vaccine. 2017;35(36):4722-4729. https://doi.org/10.1016/j.vaccine.2017.07.031
  17. Bryant LM, Christopher DM, Giles AR, Hinderer C, Rodriguez JL, Smith JB, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev. 2013;24(2):55-64. https://doi.org/10.1089/humc.2013.087
  18. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-dose genereplacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713-1722. https://doi.org/10.1056/NEJMoa1706198
  19. Smalley E. First AAV gene therapy poised for landmark approval. Nat Biotechnol. 2017;35(11):998-999. https://doi.org/10.1038/nbt1117-998
  20. Yu Y, Fu L, Jiang X, Guan S, Kuai Z, Kong W, et al. Expression of HIV-1 broadly neutralizing antibodies mediated by recombinant adeno-associated virus 8 in vitro and in vivo. Mol Immunol. 2016;80:68-77. https://doi.org/10.1016/j.molimm.2016.10.011
  21. Giles AR, Govindasamy L, Somanathan S, Wilson JM. Mapping an adeno-associated virus 9-specific neutralizing epitope to develop next-generation gene delivery vectors. J Virol. 2018;92(20):e01011-18.
  22. Penaud-Budloo M, Le Guiner C, Nowrouzi A, Toromanoff A, Cherel Y, Chenuaud P, et al. Adenoassociated virus vector genomes persist as episomal chromatin in primate muscle. J Virol. 2008;82(16):7875-7885. https://doi.org/10.1128/JVI.00649-08
  23. Shen HG, Zhou JY, Zhang X, Huang ZY, He JL, Yan Y. Interference of porcine circovirus type 2 ORF2 immunogenicity by ORF1 and ORF3 mixed DNA immunizations in mice. Virology. 2009;393(1):104-111. https://doi.org/10.1016/j.virol.2009.07.035
  24. Shen HG, Zhou JY, Huang ZY, Guo JQ, Xing G, He JL, et al. Protective immunity against porcine circovirus 2 by vaccination with ORF2-based DNA and subunit vaccines in mice. J Gen Virol. 2008;89(Pt 8):1857-1865. https://doi.org/10.1099/vir.0.2008/000125-0
  25. Seder RA, Hill AV. Vaccines against intracellular infections requiring cellular immunity. Nature. 2000;406(6797):793-798. https://doi.org/10.1038/35021239